Novel ligands designed to activate mu opioid receptors and provide analgesic effects without opioid-related side effects, providing specific insight into the cellular impact of opioid receptor-based activation as related to pain medications. These ligands could be used as a tool to negate drug tolerance and dependence as well as other adverse side effects.
An Aryl Hydrocarbon (AHR) null rat model has been generated with the CRISPR/Cas9 editing system. The rat model may be used to study how exposure to environmental pollutants (especially dioxins), acting through AHR, shapes placental development.
This invention utilizes a delivery system that allows for a biologically relevant moiety to be delivered to a desired cell by utilizing a transporting agent that binds two receptors expressed by that cell. This decreases the toxicity that is shown by the active compound by delivering it only to a targeted cell.
This innovation has two forms: a hard capsule that dissolves orally and a film that dissolves orally. The capsules can be filled with a drug formulation containing an active drug or drugs, excipients, and flavors.